A fresh study, covering “Melanoma Cancer Diagnostics Market Forecast, Trend Analysis & Competition Tracking: Global Review 2017 to 2022” has been broadcasted to wide online repository of Fact MR, which presents deep focus on the Healthcare Market. This smart study contains precise data that offers a clear insight about market current scenario and future projections for the benefit of readers. Moreover, the study enclosed significant data which tends to make the research a powerful source for analysts and industry experts who are looking to gain necessary knowledge about the prevailing market trends, opportunities and drivers present in the Melanoma Cancer Diagnostics Market.
Request For Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=57
Analysis by Test Type
By test type, the BRAF mutation test type segment will continue to be used widely for detecting the early onset of melanoma. In terms of revenue share, North America will account for majority share of revenues for the BRAF mutation segment globally. Use of BRAF mutation test type will also remain prevalent in Europe and APEJ.
The CTC segment will grow at a higher CAGR than BRAF mutation test type, with North America holding largest market share. However, it is the APEJ market where revenues will grow at the highest pace.
The immunohistochemistry segment of the global melanoma market is valued at over US$ 80 million in 2017. North America will remain the largest market for immunohistochemistry, followed by Europe and APEJ. Overall, the immunohistochemistry segment is projected to grow at a significant CAGR through 2022.
Analysis by End-Users
By end-users, the key segments of melanoma cancer diagnostics market include hospital associated labs, independent diagnostic laboratories, cancer research institutes, and ‘others’.
The hospital associated labs segment in North America is currently valued at over US$ 137 million, and is expected to grow at a steady CAGR through 2022. The hospital associated labs segment in Europe is anticipated to grow at a significant CAGR through 2022.
Independent diagnostic laboratories end-user segment in North America is expected to surpass US$ 100 million in revenues by 2022, growing at a high single-digit CAGR.
Region-wise Analysis
North America will remain an attractive market for global melanoma cancer diagnostic market. As discussed previously, BRAF mutation will remain the most widely used test type, followed by CTC. Hospital associated labs will continue to be the largest end-users in the North America melanoma cancer diagnostics market.
Europe, the second-largest market for melanoma cancer diagnostics, will continue to offer growth opportunities to manufacturers. By test type, the CTC cancer diagnostics market will continue to grow at highest CAGR, whereas hospital associated labs will be the largest end-users.
Overall, North America and Europe will continue to be the two most lucrative markets for melanoma cancer diagnostics globally.
Browse Full Report With TOC- https://www.factmr.com/report/57/melanoma-cancer-diagnostics-market
Table of Content
Chapter 1. Global Melanoma Cancer Diagnostics Market - Executive Summary. 20
Chapter 2. Global Melanoma Cancer Diagnostics Market Overview. 22
2.1. Introduction. 22
2.1.1. Global Melanoma Cancer Diagnostics Market Taxonomy. 22
2.1.2. Global Melanoma Cancer Diagnostics Market Definition. 22
2.2. Global Melanoma Cancer Diagnostics Market Size (US$ Mn) and Forecast, 2012-2022. 22
2.2.1. Global Melanoma Cancer Diagnostics Market Y-o-Y Growth. 22
2.3. Global Melanoma Cancer Diagnostics Market Dynamics. 23
2.3.1. Drivers. 23
2.3.2. Restraints. 23
2.3.3. Trends. 23
2.4. Supply Chain. 24
2.5. Epidemiology. 24
2.6. List of Distributors. 24
2.7. Average Pricing Analysis. 24
2.8. Regulations. 25
2.9. Key Participants Market Presence (Intensity Map) By Region. 25
Chapter 3. Global Melanoma Cancer Diagnostics Market Analysis and Forecast By Test Type. 26
3.1. Global Melanoma Cancer Diagnostics Market Size and Forecast By Test Type, 2012-2022. 26
3.1.1. BRAF Mutation Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 26
3.1.1.1. Revenue (US$ Mn) Comparison, By Region. 26
3.1.1.2. Market Share Comparison, By Region. 28
3.1.1.3. Y-o-Y growth Comparison, By Region. 28
3.1.2. CTC Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 29
3.1.2.1. Revenue (US$ Mn) Comparison, By Region. 29
3.1.2.2. Market Share Comparison, By Region. 31
3.1.2.3. Y-o-Y growth Comparison, By Region. 31
3.1.3. Immunohistochemistry Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 32
3.1.3.1. Revenue (US$ Mn) Comparison, By Region. 32
3.1.3.2. Market Share Comparison, By Region. 34
3.1.3.3. Y-o-Y growth Comparison, By Region. 34
3.1.4. In Situ Hybridization Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 35
3.1.4.1. Revenue (US$ Mn) Comparison, By Region. 35
3.1.4.2. Market Share Comparison, By Region. 37
3.1.4.3. Y-o-Y growth Comparison, By Region. 37
3.1.5. Others Melanoma Cancer Diagnostics Market Size and Forecast, 2012-2022. 38
3.1.5.1. Revenue (US$ Mn) Comparison, By Region. 38
3.1.5.2. Market Share Comparison, By Region. 40
3.1.5.3. Y-o-Y growth Comparison, By Region. 40
Continue…..
Request For Discount On This Report- https://www.factmr.com/connectus/sample?flag=D&rep_id=57
About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.
Contact Us
Fact.MR
Suite 9884
27 Upper Pembroke Street,
Dublin 2, Ireland
Telephone: +353-1-6111-593
Email: sales@factmr.com/
Web: https://www.factmr.com/